EU-Wide Restrictions In Store For Bayer's Prostate Cancer Drug
Executive Summary
Several medicines referred to the European Medicines Agency on issues relating to safety or benefit-risk profile are being discussed by the agency's medicines evaluation committee, the CHMP, this week.
You may also be interested in...
Bayer Eyes More Link-Ups Like Loxo After Pipeline Blips
Litigation woes at Monsanto are casting a shadow over Bayer but despite the news of some discontinued projects, the German major sees pharma as an integral component and will keep investing in its pipeline.
OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No
The European Medicines Agency this month recommended EU marketing approval for a raft of products, including what could become Europe's first two biosimilar versions of the blockbuster drug, Neulasta.
OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No
The European Medicines Agency this month recommended EU marketing approval for a raft of products, including what could become Europe's first two biosimilar versions of the blockbuster drug, Neulasta.